Literature DB >> 28704322

Malignant Bowel Obstruction in Relapsed Ovarian Cancer With Peritoneal Carcinomatosis: An Occlusive State.

Pedro Martinez Castro1, Lara Vargas, Antonio Mancheño, Salvador Martín Utrilla, Francisco Pascual, Ignacio Romero, Cristina Zorrero, José Manuel Bosch, Andrés Poveda, Lucas Minig.   

Abstract

OBJECTIVE: The aim of this study was to describe the clinical and oncological outcomes of women with malignant bowel obstruction (MBO) for relapsed ovarian cancer and peritoneal carcinomatosis.
METHODS: A retrospective cohort study was performed in all consecutive patients admitted at Instituto Valenciano de Oncología, Valencia, Spain, between July 2013 and July 2016 with MBO for relapsed ovarian cancer and peritoneal carcinomatosis. All patients underwent the same protocol of conservative management. Surgical treatment was indicated only in selected cases.
RESULTS: There were a total of 22 patients presenting 59 episodes of MBO; 17 (77.2%) of those patients presented more than 1 episode of MBO. All patients had serous epithelial ovarian cancer; 18 (81.8%) were high grade, and 4 (18.2%) low-grade tumors. The median (range) number of episodes per patient was 3 (range, 1-7) with a mean length of hospitalization of 13 (SD, 13.6) days. The median time interval between episodes of MBO (54 episodes in 17 patients) was 17 days (range, 1-727 days). Twenty of 22 patients died with a median overall survival time from the first episode of MBO of 95 days (95% confidence interval, 49-124 days).
CONCLUSIONS: Patients with MBO due to relapsed epithelial ovarian cancer in the peritoneal carcinomatosis setting have a short life expectancy, presenting a median of 3 episodes of MBO until death, with a short time interval between episodes. These findings show that bowel obstruction can represent a constant status over time until death.

Entities:  

Mesh:

Year:  2017        PMID: 28704322     DOI: 10.1097/IGC.0000000000001049

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

Review 1.  The role of parenteral nutrition in patients with malignant bowel obstruction.

Authors:  Federico Bozzetti
Journal:  Support Care Cancer       Date:  2019-07-17       Impact factor: 3.603

2.  Developing and Field Testing BOLSTER: A Nurse-Led Care Management Intervention to Support Patients and Caregivers following Hospitalization for Gynecologic Cancer-Associated Peritoneal Carcinomatosis.

Authors:  Rachel A Pozzar; Andrea C Enzinger; Hanneke Poort; Ann Furey; Heidi Donovan; Meghan Orechia; Embree Thompson; Anna Tavormina; Anny T H R Fenton; Tim Jaung; Ilana M Braun; Andrea DeMarsh; Mary E Cooley; Alexi A Wright
Journal:  J Palliat Med       Date:  2022-03-17       Impact factor: 2.947

Review 3.  Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.

Authors:  Yeh Chen Lee; Nazlin Jivraj; Catherine O'Brien; Tanya Chawla; Eran Shlomovitz; Sarah Buchanan; Jenny Lau; Jennifer Croke; Johane P Allard; Preeti Dhar; Stephane Laframboise; Sarah E Ferguson; Neesha Dhani; Marcus Butler; Pamela Ng; Terri Stuart-McEwan; Pamela Savage; Lisa Tinker; Amit M Oza; Stephanie Lheureux
Journal:  Obstet Gynecol Int       Date:  2018-05-17

4.  Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer.

Authors:  Robert D Morgan; Sofia Stamatopoulou; Nerissa Mescallado; Geoff Saunders; Richard Welch; Claire Mitchell; Jurjees Hasan; Andrew R Clamp; Gordon C Jayson
Journal:  ESMO Open       Date:  2019-03-21

5.  Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer.

Authors:  Yeh Chen Lee; Nazlin Jivraj; Lisa Wang; Tanya Chawla; Jenny Lau; Jennifer Croke; Johane P Allard; Terri Stuart-McEwan; Kashish Nathwani; Valerie Bowering; Katherine Karakasis; Catherine O'Brien; Eran Shlomovitz; Sarah E Ferguson; Sarah Buchanan; Pamela Ng; Sunu Cyriac; Lisa Tinker; Neesha Dhani; Amit M Oza; Stephanie Lheureux
Journal:  J Oncol Pract       Date:  2019-09-24       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.